Is aging itself a disease that can be treated?

Is aging really a disease, or just a natural process?

The traditional view holds that aging is a natural, inevitable decline—not a disease. But this distinction matters because regulatory agencies like the European Medicines Agency (EMA) currently do not classify aging as a disease, which limits the development and approval of anti-aging therapies [9]. A 2024 bioethics paper argues that this position is based on a flawed naturalistic argument and that reclassifying aging as a disease would have moderate positive effects, such as accelerating research into anti-aging pharmacology and increasing the chances of completing vital life projects [9]. The paper concludes that the EMA should change its stance, as the ethical consequences of doing so are desirable [9].

The scientific case for treating aging as a disease rests on the fact that aging is driven by specific, modifiable molecular and cellular mechanisms. A landmark 2022 review with over 1,370 citations [3] catalogs 12 hallmarks of aging, including genomic instability, telomere dysfunction, epigenetic alterations, loss of proteostasis, mitochondrial dysfunction, cellular senescence, and stem cell exhaustion. These are not random effects of time—they are biological processes that can be measured, targeted, and in some cases reversed. For instance, the same review notes that interventions like caloric restriction, microbiota transplantation, and senolytic drugs (which clear senescent cells) can delay or reverse aspects of aging in animal models [3].

What treatments are being developed to target aging?

Multiple therapeutic strategies are emerging, each targeting a different hallmark of aging. The most direct evidence comes from studies of senolytics—drugs that selectively kill senescent (aged) cells. A 2024 study on lupus found that treatment with a senolytic drug reduced autoimmune pathology in lupus-prone mice, directly linking the removal of senescent T cells to disease improvement [10]. Similarly, a 2025 review on cardiac aging highlights senolytics (like dasatinib and quercetin) as promising interventions to reverse age-related heart changes, including left ventricular hypertrophy and diastolic dysfunction [1]. Another 2023 review on cardiovascular aging adds metformin, SGLT2 inhibitors, and rapamycin to the list of pharmacological agents being tested [5].

Beyond drugs, lifestyle interventions are also backed by strong evidence. Caloric restriction is repeatedly cited across multiple reviews [1][3][5] as a robust way to extend healthspan, though the exact mechanisms (e.g., autophagy activation, reduced oxidative stress) are still being worked out. Natural compounds like kaempferol, a flavonoid found in plants, have shown anti-inflammatory and antioxidant effects in preclinical studies, with low toxicity and wide safety margins [11]. A 2025 review on herbal interventions for skin aging notes that polyphenols, flavonoids, and essential oils can protect and rejuvenate skin through distinct anti-aging mechanisms, and that combining them with nano-formulations improves efficacy [15].

Emerging therapies include gene editing, stem cell therapy, and microbiome modulation. A 2025 review on cardiac aging discusses these as next-generation approaches, though they are still in early stages [1]. Ovarian aging research points to stem cell therapy and ovarian tissue transplantation as potential ways to delay reproductive aging and its systemic effects on bone, brain, and heart health [2]. A 2023 review on liver aging uses multi-omics analysis to identify key pathways and targets, including the chemokine CXCL9, and suggests that targeting these could mitigate the adverse effects of liver aging [8].

How strong is the evidence that aging can be treated?

The evidence is strong at the mechanistic level but still limited in human clinical trials. Across the 15 papers reviewed, there is broad agreement that aging is driven by interconnected biological processes—oxidative stress, mitochondrial dysfunction, inflammation, epigenetic changes, and cellular senescence [1][3][5][12][14]. For example, a 2024 review on the NLRP3 inflammasome (a key immune sensor) shows that its dysfunction is linked to multiple age-related diseases, and that manipulating it could improve treatment strategies [12]. A 2022 review on iron metabolism demonstrates that iron accumulation during aging damages cells via hydroxyl free radicals, leading to mitochondrial dysfunction and brain aging, and that iron chelators are being explored as treatments [13]. The complement system, another immune component, is also implicated in aging and age-related diseases like Alzheimer's and macular degeneration [14].

However, most of the direct evidence for treating aging comes from animal models and cell studies, not large human trials. The 2022 review on nanoparticles in vascular aging notes that while nanotechnology offers promising diagnostic and therapeutic tools for age-related cardiovascular and kidney diseases, clinical applications are still limited [4]. A 2023 review on brain aging and histone methylation points to neuroprotective drugs and natural compounds as potential therapies, but emphasizes that these are still in the exploratory phase [6]. The 2022 review on innate immunity in the aging eye similarly describes approaches to restore protective immune functions, but does not report results from human trials [7].

The most cited paper among these—a 2022 review with over 1,370 citations [3]—provides a comprehensive framework but is itself a synthesis of existing research, not a single experiment. The only direct experimental evidence of a treatment effect in a disease model comes from the lupus study [10], which used a senolytic drug in mice. This is promising but far from proof in humans. In short, the evidence strongly supports the idea that aging is a treatable condition, but the treatments are mostly in early development, and regulatory hurdles remain a significant barrier [9].

About These Sources

This answer is built on 15 peer-reviewed studies — published from 2022 to 2025, 7 from 2024 or later, 12 in Q1 journals, collectively cited 1,891 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 64 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions